GLP-1 Medications and Michigan Medicare Coverage: What Changed in 2026

Key takeaways

• Since July 1, 2026, the Medicare GLP-1 Bridge lets eligible Part D members get Wegovy or Zepbound for $50 a month.
• The Bridge is temporary (through December 2027) and requires a BMI of 30+, or 27+ with a weight-related condition.
• Michigan Medicaid cut GLP-1 weight-loss coverage on January 1, 2026 to type 2 diabetes or a BMI of 40+.
• The Treat and Reduce Obesity Act would make Medicare coverage permanent but has not passed.
• If you fall in the gap, self-pay programs at Arbour Longevity start at $299/month after a $35 first visit.

The Medicare GLP-1 Bridge Program: A Historic First

On July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare GLP-1 Bridge. It is the first federal program that lets Medicare Part D members get GLP-1 drugs for weight management at a fixed cost of $50 per month. GLP-1 drugs, such as semaglutide and tirzepatide, mimic a gut hormone to curb appetite and steady blood sugar. This is a seismic shift. Until now, federal law barred Medicare from covering drugs prescribed only for weight loss. Millions of older adults paid out of pocket for drugs that can cost over $1,000 a month at retail.

The Bridge is a temporary demonstration (a test program) that runs through December 2027. It covers FDA-approved GLP-1 drugs indicated for chronic weight management, including semaglutide (Wegovy) and tirzepatide (Zepbound). Drugs prescribed only for type 2 diabetes, such as Ozempic and Mounjaro, are already covered under standard Part D and are handled on their own.

Who Is Eligible for the Medicare GLP-1 Bridge?

To qualify for the Bridge program, Medicare members must meet all of the following:

• Enrolled in a Medicare Part D plan (standalone, or through a Medicare Advantage plan with drug coverage)
• BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity (a second health problem). Examples: type 2 diabetes, high blood pressure, abnormal cholesterol, obstructive sleep apnea, or heart disease.
• Prescribed by an eligible provider who documents medical need and agrees to the program's prescribing rules

There are real limits. The program has capacity limits, so not everyone who qualifies will get in right away. CMS has said it will put members with the highest clinical need first.

The Bridge is also separate from the broader BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health). BALANCE is a CMS Innovation Center test program announced in January 2026. It aims to build a longer-term framework for GLP-1 access in both Medicare and Medicaid. It is still in early rollout and may reshape coverage further in 2027 and beyond.

The TREAT Act: Permanent Coverage on the Horizon?

The Bridge is temporary, but Congress is weighing a permanent fix. The Treat and Reduce Obesity Act (TROA) was reintroduced in the 119th Congress in 2025 as both H.R. 4231 and S. 1973. This bill has backers from both parties. It would amend the Social Security Act to require Medicare Part D to cover FDA-approved anti-obesity medications. That would end the long-standing legal exclusion for good.

The bill has broad support from medical societies and patient groups. As of this writing, it has not passed. If it becomes law, GLP-1 coverage would be a standard Medicare benefit rather than a time-limited test. That would give a stable answer to the millions of older Americans living with obesity.

Stuck in the coverage gap?
Your $35 first visit includes a full metabolic review and a clear, insurance-free price for GLP-1 therapy, with the $35 applied toward your program.
Book your $35 first visit Call (734) 436-3357

Michigan Medicaid Took the Opposite Path

While Medicare opened a door at the federal level, Michigan Medicaid closed one. On January 1, 2026, the Michigan Department of Health and Human Services sharply cut GLP-1 coverage for Medicaid members. The state projected savings of about $240 million from the change.

Before January 2026, Michigan Medicaid covered GLP-1 drugs for weight management at a BMI of 30 or greater. It also covered a BMI of 27 or greater with at least one obesity-related health problem. Since January 1, 2026, coverage for weight management is limited to patients who meet one of two criteria:

• A diagnosis of type 2 diabetes, where GLP-1 drugs serve both blood sugar control and weight management
• A BMI of 40 or greater (morbid obesity), with prior authorization required

As a result, tens of thousands of Michigan Medicaid members with a BMI between 27 and 39.9 lost GLP-1 coverage for weight management at the start of 2026. Experts at the University of Michigan Institute for Healthcare Policy and Innovation call this a hard spot for patients and doctors. Patients may be taken off drugs that were working. That can lead to weight regain and worse obesity-related disease.

What the Research Shows About GLP-1 Coverage and Cost

A growing body of research shapes the coverage debate in Michigan and nationwide. A 2025 cost analysis looked at wider Medicare coverage of GLP-1 drugs for obesity. It put the drug cost at about $65.9 billion over 10 years. That would be offset by $18.2 billion in health care savings from fewer obesity-related problems such as heart disease, stroke, and diabetes. The authors noted that even modest uptake would bring real clinical benefit. They stressed that further drug price cuts are needed to make coverage affordable long term (JAMA Health Forum, 2025; DOI: 10.1001/jamahealthforum.2025.0905).

A 2026 synopsis came out of a workshop held by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It found that GLP-1 coverage still varies widely across Medicare, Medicaid, and private plans. The workshop concluded that real-world data is needed to build coverage rules based on value, as GLP-1 use keeps growing fast (Annals of Internal Medicine, 2026; DOI: 10.7326/ANNALS-25-05468).

Falling Through the Gaps: What Are Your Options?

Right now, many Michigan patients sit in a coverage gap. You may be on Medicare but not meet the Bridge rules, or not get a spot. You may be on Medicaid with a BMI under 40 and no diabetes. Either way, insurance alone may not give you a path to GLP-1 therapy you can afford.

This is where a clinic like ours can help. At Arbour Longevity in Ann Arbor, we work with patients in every insurance situation. Our clinician-led weight loss programs start at $299/month with medication included. Our approach includes:

• A full metabolic workup to find the right treatment path for your body
• Access to GLP-1 and other evidence-based weight loss drugs at clear, competitive pricing
• Ongoing support from Gandhi Bhattarai, FNP-BC, PMHNP-BC, a triple board certified nurse practitioner
• Lifestyle and food guidance built into your plan for results that last

Whether you are fighting insurance red tape or simply want medical help with your weight, our clinic can get you care without the runaround.

Frequently Asked Questions

Does Medicare cover Wegovy or Zepbound for weight loss in Michigan in 2026?

Yes, with limits. As of July 1, 2026, the Medicare GLP-1 Bridge lets eligible Medicare Part D members get Wegovy (semaglutide) and Zepbound (tirzepatide) for weight management at a fixed $50 per month. You need a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, plus a prescription from an eligible provider. The program runs through December 2027.

Does Michigan Medicaid still cover GLP-1 medications for weight loss?

Only in narrow cases. Michigan Medicaid sharply cut GLP-1 coverage for weight management on January 1, 2026. Coverage is now limited to patients with type 2 diabetes or a BMI of 40 or greater. Patients with a BMI between 27 and 39.9 who were covered for weight alone no longer qualify unless they have a diabetes diagnosis.

What if I do not qualify for Medicare or Medicaid GLP-1 coverage?

You can still get GLP-1 drugs through clinics that offer self-pay pricing and full weight-loss support. Arbour Longevity in Ann Arbor offers clinician-led programs with clear pricing and tailored care, even with no insurance.

Will Medicare permanently cover GLP-1 medications for obesity?

Not yet. The Medicare GLP-1 Bridge is a temporary test program that ends in December 2027. The Treat and Reduce Obesity Act (TROA) is now before Congress with support from both parties. If passed, it would make Medicare coverage of FDA-approved anti-obesity medications permanent. Its fate will decide long-term access for millions of older adults.

Arbour Longevity is a longevity, hormone, and regenerative medicine clinic. Find us at 2217 Packard St #15, Ann Arbor, MI 48104. We are open Thursday through Monday, 10am to 7pm. Your care comes from Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC, who is triple board certified. Your first visit is $35, applied toward your treatment plan. Book your $35 first visit or call (734) 436-3357.